Halozyme Therapeutics, Inc.
HALO
$47.91
-$2.32-4.62%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 53.72% | 60.46% | 67.42% | 24.74% | 93.92% |
| Total Depreciation and Amortization | 1.20% | -1.34% | -1.06% | -1.44% | -1.23% |
| Total Amortization of Deferred Charges | 0.87% | 0.88% | 0.93% | 0.99% | -0.27% |
| Total Other Non-Cash Items | -29.45% | -130.05% | 66.00% | 24.99% | -19.83% |
| Change in Net Operating Assets | -65.34% | 197.21% | -344.22% | -69.70% | 56.04% |
| Cash from Operations | 19.16% | 74.36% | -12.87% | -16.53% | 48.83% |
| Capital Expenditure | 73.20% | -17.57% | 48.47% | -259.09% | 68.84% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -13.06% | 671.24% | -106.15% | -173.93% | -62.21% |
| Cash from Investing | -9.36% | 455.57% | -100.70% | -176.44% | -37.43% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 50.63% | 352.60% | 287.65% | -- |
| Repurchase of Common Stock | -579.14% | 0.91% | -- | -- | 99.68% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -579.14% | 1.40% | 352.60% | 287.65% | 99.70% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 30.74% | 75.32% | -163.22% | -81.30% | 133.57% |